NCT03272633 · REGISTRY CONDITION SEARCH

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: EARLY PHASE1
Status at capture: TERMINATED
Registry last update: 2023-06-26

This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving a stem cell transplant.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants Who Received Irradiated Haploidentical Cells (IHC) With Disease Response

→

outcome · POSTED

the Number of Participants With Toxicities Associated With Administration of Irradiated Haploidentical Cells (IHC) Evaluated According to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

→

outcome · POSTED

Induction of Host T Cells Reactive With Tumor Associated Epitopes

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Patient with disease (stage) eligible per cohort * COHORT 1: patients undergoing high dose chemotherapy with autologous stem cell rescue and ?high-risk? disease as defined below: * Diffuse large cell lymphoma or peripheral T cell lymphoma (including specified World Health Organization \[WHO\] subtypes) not in computed tomography (CT)-positron emission tomography (PET) complete remission at time of high dose therapy * Diffuse large cell lymphoma with ?double hit? or ?double expressor? features * Diffuse large cell lymphoma or peripheral T cell lymphoma (including WHO specified subtypes) refractory to standard induction therapy OR relapsing within 1 year of treatment OR in greater that second complete remission (CR) * Mantle cell lymphoma not in CR1 * Multiple myeloma with ONE (or more) of the following high risk features: * Less than very good partial remission at time of high dose therapy * High Revised-International Staging System (R-ISS) (stage III ? 2 microglobulin \>= 5.5 plus lactate dehydrogenase \[LDH\] \> upper limit of normal \[ULN\] and/or del17p, t(4;14), t(14;16)) at time of diagnosis * Cytogenetics or fluorescent in situ hybridization (FISH) del17p * COHORT 2: patients with high risk disease having undergone an allogeneic hematopoietic stem cell transplant from a 10/10 human leukocyte antigen (HLA) matched donor with one of the following disease subtypes: * Acute myeloid leukemia (AML) in CR1 with high risk features (European Leukemia Network \[ELN\]) at presentation * Diagnostic sample with either t(6;9), t(9;22), 11q23, inv 3, -5, -7, del17p, complex cytogenetics, NPMwt-flt3ITD+, OR p53 mutation (mut); patients whose samples have mutations in RUNX1 or ASXL1 are also eligible (unless the patient has favorable cytogenetics) * AML in CR1 with measurable minimal residual disease (MRD) by molecular (e.g., myeloid mutation profile, polymerase chain reaction \[PCR\] for NPM1, core-binding factor \[CBF\], mixed lineage leukemia \[MLL\]) or flow cytometry * AML not in CR1 (including patients with morphologic CR but with incomplete recovery, CRi) * Myelodysplastic syndrome (MDS) with complex cytogenetics, 17p deletion or p53 mutation, or JAK2 or RAS mutation * Treatment-related MDS or AML * Acute lymphoblastic leukemia (ALL) not in CR1 * ALL with MRD * Any hematologic malignancy relapsed or with persistent disease after allogeneic hematopoietic stem cell transplant * Multiple myeloma * Non-Hodgkin lymphoma (NHL) with chemoresistant disease at time of transplant * Any patient undergoing allogeneic hematopoietic stem cell transplant and an anticipated rate of relapse \> 80% based upon published data and for which there is consensus amongst the Hematologic Malignancies Tumor Study Group that enrollment is appropriate * Availability of a genetic child, genetic parent or sibling as a potential HLA haploidentical donor * Meets standard eligibility requirements for high dose chemotherapy with autologous stem cell rescue (COHORT 1) or allogeneic hematopoietic stem cell transplant (COHORT 2) and has signed consent for those procedures * DONOR: Donor must be related to patient and be partially (\>= 3/6 antigen) HLA-matched * DONOR: Donor must meet all Robert Wood Johnson (RWJ) Blood Services requirements for hematopoietic stem cell donation including: * Age \>= 18 years old; * Normal hemogram (white blood cells \[WBC\] 4.0-10.0 x 10\^3/mm\^3; platelet count 150,000 to 440,000/mm\^3 ; hemoglobin/hematocrit; 12.5-18 g/dl, 38 to 54% * Not pregnant or lactating; * Not human immunodeficiency virus (HIV)-1, HIV-2, hepatitis C virus (HCV), hepatitis B core or human T-cell lymphotropic virus (HTLV)-I/II seropositive; hepatitis B surface antigen (HB S ag) (-); meet other infectious disease screening criteria utilized by RWJ Blood Services; * No uncontrolled infections, other medical or psychological/social conditions, or medications that might increase the likelihood of patient or donor adverse effects or poor outcomes; * Meet other blood bank criteria for blood product donation (as determined by RWJ Blood Center screening history and laboratory studies) Exclusion Criteria: * Non-English speaking person * Patients undergoing haploidentical allogeneic hematopoietic stem cell transplants are not eligible; patients undergoing \< 10/10 HLA allele matched allogeneic transplant are not eligible * Pregnant women * DONOR: Non-English speaking person * DONOR: Pregnant women
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
intervention Names
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: Irradiated Allogeneic Cells
label
Cohort I (initial IHC within 42 days)
type
EXPERIMENTAL
description
Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
intervention Names
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: Irradiated Allogeneic Cells
label
Cohort II (initial IHC within 70 days or after relapse)
type
EXPERIMENTAL

interventions

arm Group Labels
Cohort I (initial IHC within 42 days)
Cohort II (initial IHC within 70 days or after relapse)
description
Receive IHC
name
Allogeneic Hematopoietic Stem Cell Transplantation
other Names
Allogeneic Hematopoietic Cell Transplantation
allogeneic stem cell transplantation
HSC
HSCT
type
PROCEDURE
arm Group Labels
Cohort I (initial IHC within 42 days)
Cohort II (initial IHC within 70 days or after relapse)
description
Correlative studies
name
Irradiated Allogeneic Cells
type
BIOLOGICAL

Study design

allocation

NON_RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 2
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
measure
Number of Participants Who Received Irradiated Haploidentical Cells (IHC) With Disease Response
time Frame
Up to 8 weeks after last protocol treatment
description
The anticipated/projected IHC-associated toxicities of greatest concern include: short-term toxicities- constitutional/systemic adverse events including fevers, hypotension, pulmonary infiltrates; long-term toxicities: autoimmune effects, graft-versus-host disease (GVHD), graft rejection. Toxicity will be measured by occurrence of any experimental treatment-related adverse events (AE) up to 12 weeks of completion of therapy. The CTCAE version 4.0 will be utilized for the description and grading of the AE. All symptoms, signs, or diseases assessed as experimental treatment-related will be captu
measure
the Number of Participants With Toxicities Associated With Administration of Irradiated Haploidentical Cells (IHC) Evaluated According to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
time Frame
Up to 12 weeks of completion of therapy

secondary Outcomes

description
It will be determined if treatment with the irradiated cells induces an immune response targeting tumor associated epitopes.
measure
Induction of Host T Cells Reactive With Tumor Associated Epitopes
time Frame
Up to 8 weeks after last protocol treatment

Full study description

brief Summary: This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving a stem cell transplant.
detailed Description: PRIMARY OBJECTIVES: I. To determine the toxicity associated with the administration of irradiated haploidentical cells (IHC) to patients with high-risk hematologic malignancies. SECONDARY OBJECTIVES: I. To determine if there is evidence of disease response associated with IHC. TERTIARY OBJECTIVES: I. To determine if treatment with the irradiated cells induces an immune response targeting tumor associated epitopes. OUTLINE: Patients are assigned to 1 of 2 cohorts. COHORT I: Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous hematopoietic stem cell transplantation (HSCT), patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses. COHORT II: Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses. After completion of study treatment, patients will be followed up within 8 weeks.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-84584a80851d8fafc422
requested nct id
NCT03272633
primary nct id
NCT03272633
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
73f4b5f7aff1239cd3cd1102123ded24a40ab2591d4cf0c5a06cda8ce8c1b953
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-84584a80851d8fafc422
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT03272633
occurrences
context exact
NCT03272633
end
11
exact text
NCT03272633
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/863/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
6d698187be49a21eea04833cfa6e2c76582b259ea060de0d1093ce087990e2c8
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice